Impact of lifestyle modification practices and pharmacogenetics of ACE I/D gene polymorphism in grade 1 hypertensive patients Authors: Farhana Rahman, Suguna Elumalai, Shanmugapriya Arumugam, Ashni Bhandari, Krishna Prasanth, Nagasundaram Muthiah, Govindasamy Kumaramanickavel Published: 2025 ABSTRACT ABSTRACTBackground:Hypertension is a chronic disease whose prevalence is gradually increasing in society. It causes disease burden for a country, especially in low and middle-income countries. The present study aimed at analysing the impact of lifestyle modification practices and the role of pharmacogenetics of anti-hypertensive drugs in hypertensive patients susceptible to ACE I/D polymorphisms.Materials and Methods:A hospital-based cross-sectional study was done on 447 hypertensive patients (grade 1) with age >20 years, both genders, with and without co-morbid diseases, taking anti-hypertensive drugs for more than one year, were recruited for the study. By convenience sampling method, 100 hypertensive patients taking amlodipine (5 mg/day) or telmisartan (20 mg/day) for more than one year were enlisted from the initially recruited study group, along with 100 healthy volunteers.Results:Patients who practiced various lifestyle modifications were seen to have good control (P < 0.05) of hypertension. ACE I/D gene polymorphism was significantly (P = 0.04) associated with hypertension when compared to control subjects. The distribution of the study subjects showed deviation from Hardy–Weinberg Equilibrium (P = 0.001). Amlodipine (5 mg/day) in ACE II and telmisartan (20 mg/day) in ACE DD genotype showed better control of blood pressure among the study population.Conclusion:The present study showed that lifestyle modification along with individualized drug therapy is vital in controlling blood pressure in grade 1 hypertensive patients. Introduction Hypertension is a chronic disease with multifactorial etiologies. A study shows, intervention of lifestyle modification plays a vital role in the management of hypertension.[1] Genetics contributes around 30–50% of blood pressure variations in humans,[2] and according to GWAS (genome-wide association studies), various SNPs (single-nucleotide polymorphisms) were found to be linked with hypertension.[3] The human ACE gene is on chromosome 17q23. Angiotensin-converting enzyme insertion/deletion (ACE I/D or rs1799752) is a common variant of the ACE gene located in intron 16.[4] A meta-analysis of eight studies from the African sub-continent shows that the ACE I/D gene polymorphism is associated with essential hypertension.[5] Very few similar studies have been done in India, but these studies showed varied responses.[67] It has been a known fact that increased salt consumption in the diet leads to hypertension and other cardiovascular complications. Salt sensitivity refers to the physiological trait of those individuals whose kidney function is altered and requires higher arterial pressure to excrete a given amount of sodium, leading to hypertension and complications. Studies from different parts of the world reported that the ACE I/D gene polymorphism is associated with salt-sensitive hypertension.[89] Interindividual variability in drug response can be seen due to genetic variants of the patients. Genetic polymorphisms with respect to absorption, distribution, metabolism, and excretion (pharmacokinetic) or polymorphism of the gene encoding the receptor leading to upregulation or downregulation of the receptor (pharmacodynamic) might influence the therapeutic response of a drug in an individual.[10] Few pharmacogenetic studies from elsewhere stated that hypertensive subjects with ACE II genotypes on irbesartan and ACE DD genotypes on enalapril and lisinopril showed significant (P < 0.01) lowering of BP.[1112] It has been seen from many clinical trials that comprehensive lifestyle interventions help in lowering blood pressure in hypertensive patients. But sometimes, due to the lack of targeted therapy, even lifestyle interventions and drug therapy cannot achieve the optimal blood pressure in patients. We have selected the ACE gene, ACE I/D genetic variation, for the pharmacogenetic study, as previous studies from elsewhere state that ACE I/D polymorphism is associated with salt-sensitive hypertension, and people living in coastal regions were found to consume more salt in their diet. Since lifestyle intervention studies and pharmacogenetic knowledge on various drugs for anti-hypertensive therapy is quiescent in India, henceforth we selected this topic as our present study. Materials and Methods Study area and period The study was conducted from the year 2017 to 2020 in a metropolitan city in the southern parts of India. Study design and population Hospital-based cross-sectional study design was conducted among adult hypertensive patients attending the host institute. Inclusion and exclusion criteria Age > 20 years, both genders, hypertensive patients (Grade 1: 140-159/90-99 mm of Hg[13] with or without co-morbid diseases taking anti-hypertensive drugs for more than one year were recruited for the lifestyle modification practice study. For the pharmacogenetic study group, hypertensive patients who were on calcium channel blocker – Amlodipine (5 mg) or angiotensin receptor blocker – Telmisartan (20 mg) once daily for more than one year were selected with consent from the lifestyle modification practice study group. The study also included healthy volunteers, aged >20 years, both genders, from the residents of the surrounding study area. BP (blood pressure) was measured three consecutive times at an interval of five minutes by the IHS (International Society of Hypertension) guidelines. However, pregnant and lactating mothers and terminally ill patients are excluded from both lifestyle modification practice and the pharmacogenetic study group. Definition of hypertension The definition of hypertension is based on the ISH guidelines committee when SBP (Systolic Blood Pressure) is 140 mm of Hg or greater and/or DBP (Diastolic Blood Pressure) is 90 mm of Hg or greater is diagnosed as hypertension.[13] Sample size For the Lifestyle Modification Practice Study: 447For Pharmacogenetic Study: 100 – healthy volunteers, 100 – hypertensive subjects For the Lifestyle Modification Practice Study: 447 For the Lifestyle Modification Practice Study: 447 For Pharmacogenetic Study: 100 – healthy volunteers, 100 – hypertensive subjects For Pharmacogenetic Study: 100 – healthy volunteers, 100 – hypertensive subjects Sampling method Due to the limitation of time and lack of funds, the purposive sampling method was applied in the lifestyle modification practice study group. For the pharmacogenetic study, a convenience sampling method was applied, and the participants were recruited based on their anti-hypertensive drug therapy. Data collection Lifestyle modification practice study group data collection A structured questionnaire was designed and reviewed by experts in the field of study. The questionnaire was to assess the lifestyle modification practices of the hypertensive patients. Pharmacogenetic study group data collection 6 mL of peripheral blood was collected in EDTA vials, one from the patient and also from the healthy volunteers. Blood samples were stored at –20°C for further genetic analysis. Genotyping of I/D polymorphism DNA was extracted from the peripheral blood with the QIAamp Blood DNA Mini Kit (QIAGEN, Germany). The purity of the DNA was determined from the 260/280 ratio measurement on the Nanodrop spectrophotometer. DNA quantity for a double-stranded DNA was calculated using the formula 1OD260 = 50 ng/μL. To determine the I/D polymorphism of the ACE gene, forward 5′-CTG GAG ACC ACT CCC ATC CTT TCT3′ and reverse 5′-GAT GTG GCC ATC TTC GTC AGAT-3′ gene primers were used. PCR amplification reaction was performed with a 20 μL reaction mixture. Gel electrophoresis was used to separate DNA from the PCR product. The gel was viewed under UV light using a transilluminator. Results are interpreted according to the position of the bands with the 100 bp ladder as a molecular marker. DNA sequencing of the amplified DNA was done by the Sanger method. Statistical analysis Statistical Package for Social Sciences (SPSS 17) software was used for descriptive and inferential statistical analysis. For the Questionnaire Survey (Lifestyle Modification Practice) Analysis: Continuous data were given as mean. The Chi-square (χ2) test was used to analyze the categorical values. Probability values (‘P’ value) of < 0.05 were considered statistically significant.For the Pharmacogenetic Study Analysis: Hardy–Weinberg equilibrium (HWE) of the SNP was assessed by the Chi square test (χ2). Odds ratio (OR) for the measurement of association. For the Questionnaire Survey (Lifestyle Modification Practice) Analysis: Continuous data were given as mean. The Chi-square (χ2) test was used to analyze the categorical values. Probability values (‘P’ value) of < 0.05 were considered statistically significant. For the Questionnaire Survey (Lifestyle Modification Practice) Analysis: Continuous data were given as mean. The Chi-square (χ2) test was used to analyze the categorical values. Probability values (‘P’ value) of < 0.05 were considered statistically significant. For the Pharmacogenetic Study Analysis: Hardy–Weinberg equilibrium (HWE) of the SNP was assessed by the Chi square test (χ2). Odds ratio (OR) for the measurement of association. For the Pharmacogenetic Study Analysis: Hardy–Weinberg equilibrium (HWE) of the SNP was assessed by the Chi square test (χ2). Odds ratio (OR) for the measurement of association. Results In the present study, 54.5% were female and 45.5% were male, 53.32 ± 11.2 was the mean age of the hypertensive patient, 144.81 ± 14.9 mm of Hg and 90.81 ± 7.6 mm of Hg were systolic and diastolic blood pressure, respectively. The mean body weight of the study group was 66.49 ± 10.7, and the duration of hypertension was 5.21 ± 4.9. Assessment of lifestyle modification practice of the hypertensive patients in association with control of blood pressure Lifestyle modification practices such as – intake of less salt in diet (P = 0.04), low fat dairy products intake (P = 0.03), reduce intake of oily food (P = 0.01), daily physical exercise brisk walking, cycling, jogging etcetera for thirty (P = 0.04), intake of vegetables (P = 0.02), managing weight reduction with physical exercise or diet planning (P = 0.04) and managing stress with yoga, meditation, good sleep etcetera (P = 0.04) were observed to have better control of hypertension among the study subjects [Table 1]. Table 1Assessment of behavioural modification (lifestyle modification) practice of the patient and its association with blood pressure controlItem questionNumber of patients practised (n=447)Odd ratio P Salt reduction in diet (1 teaspoon/day or <5 gm/day)325 (72.7%)0.9 0.04 Intake of low-fat dairy products281 (62.8%)0.5 0.03 Reduced amount of fatty and oily food328 (73.37%)0.1 0.01 Daily intake of vegetables429 (95.9%)1.83 0.02 Daily exercise for 30 mins (brisk walking, jogging, cycling)214 (47.8%)0.1 0.04 Daily intake of fruits277 (61.9%)0.43 0.03 Cessation of smoking32 (7.1%)0.460.30Managing stress60 (13.4%)0.3 0.04 Limit alcohol intake48 (10.7%)0.400.36Once daily lean meat/fish376 (84.1%)2.40.44Maintenance of weight reduction during treatment305 (68.2%)3.65 0.04 Bold letters show P value significant P<0.05 Assessment of behavioural modification (lifestyle modification) practice of the patient and its association with blood pressure control Bold letters show P value significant P<0.05 History of salt intake in diet by the hypertensive patient enrolled for pharmacogenetic study The history of salt intake in the diet was taken from the patients who were enrolled in the pharmacogenetic study. Item questions were designed to correlate phenotypically high salt intake in diet and hypertension [Table 2]. Table 2History of salt intake by the patient subject enrolled for the pharmacogenetic studyItem questionYes (values given in %)No (values given in %)Add salt to food before eating7525Eating processed food such as pickles, processed fish or meat, papad, etc928Limit the intake of salt in the diet after high blood pressure is detected8713Awareness regarding high intake salt may lead to high blood pressure919Family history of high blood pressure3763 History of salt intake by the patient subject enrolled for the pharmacogenetic study Detection of ACE I/D polymorphisms After PCR amplification, DNA fragments (3 μL) were stained with ethidium bromide (2 μL) and visualized under UV light. DNA product shows a 190 bp (base pair) fragment in case of deletion (D allele) and a 490 bp fragment in case of insertion (I allele). Hence, after electrophoresis, the PCR fragment shows three genotypes, such as - 490 bp band (II), a 190 bp band (DD), and both 490 bp and 190 bp bands (ID) as shown in Figure 1. Gel picture of I/D polymorphism of ACE gene. Extreme left of the gel picture shows the 1 kb DNA ladder. Lane 1, 6, 16 shows homogenous DD genotype. Lane 4, 5, 12, 13 shows homogenous II genotype. Lane 2, 3, 7, 8, 9, 10, 11, 14, 17, 18, 19, 20 shows heterozygous ID genotype Genetic and allelic frequencies of I/D polymorphism of ACE gene among hypertensives and normotensives ACE I/D gene polymorphism is significantly associated with hypertension when compared to control subjects (P = 0.04). The distribution of the study subjects showed deviation from Hardy Weinberg Equilibrium (P = 0.001) [Table 3]. Table 3Genetic frequencies of I/D polymorphism of ACE gene among hypertensives and normotensivesACE genotypesHypertensive n=100Normotensive n=100 P Hardy Weinberg Equilibrium PII46 (46%)38 (35%)0.04Chi sq goodness, fit=34.03, df=2, P=0.001DD31 (31%)18 (18%)ID23 (23%)44 (47%)P value shows significant P<0.05 Genetic frequencies of I/D polymorphism of ACE gene among hypertensives and normotensives P value shows significant P<0.05 I allele frequency is higher in the study population when compared with the D allele (P = 0.002). So, II is taken as the dominant genotype and DD as the recessive genotype [Table 4]. ACE I/D polymorphism was significantly associated with the dominant model (P = 0.03) [Table 5] and the recessive model (P = 0.02) [Table 6]. Table 4Allele frequencies of I/D polymorphism of the ACE gene among hypertensives and normotensivesACE genotypesHypertensive n=100Normotensive n=100 P I115 (57.5%)120 (60%)0.002D85 (42.5%)80 (40%)P value shows a significant P<0.05 Allele frequencies of I/D polymorphism of the ACE gene among hypertensives and normotensives P value shows a significant P<0.05 Table 5Dominant model to show the association of the ACE I/D gene polymorphism with the hypertensive study groupDominant model GroupsACE I/D genotypesOR (odds ratio) P IIID + DDHypertensive46545.60.03Normotensive35622P value shows a significant P<0.05 Dominant model to show the association of the ACE I/D gene polymorphism with the hypertensive study group P value shows a significant P<0.05 Table 6Recessive model to show the association of the ACE I/D gene polymorphism with the hypertensive study groupRecessive model GroupsACE I/D genotypesOR (odds ratio) P DDID + IIHypertensive316940.02Normotensive18820.6P value shows a significant P<0.05 Recessive model to show the association of the ACE I/D gene polymorphism with the hypertensive study group P value shows a significant P<0.05 The percentage of ACE ID genotype is higher in the control group (47%) as compared to the hypertensive group (23%). Association of drug intake and ACE II, DD, and ID genotypes Amlodipine 5 mg shows good control of hypertension (76.1%) when compared with Telmisartan 20 mg (43.7%) for the ACE II genotypes [Table 7]. Table 7Association of drugs intake and ACE II genotypes hypertensive patients ACE II genotypes DrugsNumber of patients taking drugNumber of patient able to control BP (%)Number of patients not able to control BP (%)Amlodipine2116 (76.1%)5 (23.8%)Telmisartan167 (43.7%)9 (56.2%)Amlodipine + Telmisartan95 (55.5%)4 (44.4%)Bold letter shows higher percentage of BP control Association of drugs intake and ACE II genotypes hypertensive patients Bold letter shows higher percentage of BP control For the ACE DD genotypes, Telmisartan 20 mg showed a better control of blood pressure (83.3%) when compared with Amlodipine 5 mg (43.7%) [Table 8]. Table 8Association of drugs intake and ACE DD genotypes hypertensive patients ACE DD genotypes DrugsNumber of patients taking drugNumber of patient able to control BP (%)Number of patients not able to control BP (%)Amlodipine167 (43.7%)9 (56.2%)Telmisartan1210 (83.3%)2 (16.6%)Amlodipine + Telmisartan31 (33.3%)2 (66.6%)Bold letter shows higher percentage of BP control Association of drugs intake and ACE DD genotypes hypertensive patients Bold letter shows higher percentage of BP control Heterogeneous group, ACE ID genotypes did not show any control of BP with either Amlodipine or Telmisartan [Table 9]. Table 9Association of drugs intake and ACE ID genotypes hypertensive patientsACE ID genotypes DrugsNumber of patients taking drugNumber of patient able to control BP (%)Number of patients not able to control BP (%)Amlodipine124 (33.3%)8 (66.6%)Telmisartan52 (40%)3 (60%)Amlodipine + Telmisartan63 (50%)3 (50%) Association of drugs intake and ACE ID genotypes hypertensive patients Discussion A healthy lifestyle is vital for the prevention of cardiovascular diseases and their complications, but in recent years, it has decreased due to rapid urbanization and unhealthy lifestyles. Even though there are several classes of antihypertensive drugs for treating hypertension, there is individuality in therapeutic response or frequency of adverse effects of a drug, which could influence both pharmacokinetic and pharmacodynamic mechanisms underlying the drug responses.[14] However, there is a dearth of knowledge regarding pharmacogenetic studies in our geographic region. Henceforth, analysis of lifestyle modifications, genetic variation of an individual, and pharmacotherapy would be a better management of hypertension. Our present study aims at analysing these variables in hypertensive patients visiting an urban health care centre in South India with respect to blood pressure control. The International Society of Hypertension (ISH) 2020 guidelines were approved, and the American Heart Association (AHA) recommended the Dietary Approaches to Stop Hypertension (DASH) and various lifestyle modifications to control hypertension. In many cross-sectional studies, unhealthy diets (unprocessed red meats, processed meats, sugar-sweetened beverages, saturated fat, trans fat, dietary cholesterol) and high dietary intake of sodium were reported to have a positive, linear, and significant association with hypertension.[15] Various lifestyle modifications have been approved by the ISH 2020 guidelines, along with pharmacotherapy, for better management of hypertension. In the present study, it was also observed that subjects who adopted lifestyle changes had better control of their blood pressure [Table 1]. With the advent of the genomic era, hypertension is considered a complex trait, commonly polygenic, and environmental influences may exert epigenetic changes, which could even be transmitted across several generations. Pathophysiological and experimental evidence suggested that high salt intake increases blood pressure in salt-sensitive patients due to stimulation of the sympathetic nervous system and a decrease in plasma aldosterone, but salt-resistant patients did not respond after sodium loading.[16] We took a questionnaire survey of the history of salt intake among the subjects recruited for a pharmacogenetic study to assess the behaviour of salt intake in the diet before the diagnosis of hypertension. It was found that 92% of the patients took processed food, and 62% of them had the habit of adding extra salt in their food before consuming [Table 2]. It was reported from some parts of the world that ACE, a salt-sensitive gene and its polymorphisms, ACE I/D, have been associated with essential hypertension. But some ethnic communities did not show any association with this genetic polymorphism. Recently, a computational model explored the effect of ACE I/D polymorphism on haemodynamic parameters and concluded that the association of ACE I/D gene polymorphism with BP depends on serum ACE activity. The higher the serum ACE activity, lack of association of this genetic polymorphism with BP.[17] Hence, a meta-analysis of the African population showed an association[5] while ethnic races, non-Hispanic white, non-Hispanic black, and Mexican American did not show any association with ACE I/D gene polymorphism and hypertension.[18] Similarly, Indian studies also reported mixed results from Kashmiri[19] and Punjabi populations[7] from northern India and two studies from southern parts of India.[620] In our present study, ACE I/D gene polymorphism showed a significant (P = 0.04) association with hypertension when compared with controls (normotensive). But neither of these above authors nor we have tested for serum ACE activity in the study population. The distribution of genotypes in the present study subjects showed deviation from the Hardy-Weinberg equilibrium (P = 0.001), indicating that the selective samples were representative of the study population. The frequency of both ACE II and ACE DD genotypes was higher among hypertensive patients in comparison to the control subjects. Nonetheless, the ACE ID genotype was higher in the control group (47%) when compared with the hypertensive group (23%) [Table 3]. Hence, the ACE ID genotype could be considered a protective factor against hypertension, as per our data in our study subjects. Both the dominant model (II vs. ID + DD) (P = 0.03) with adjusted OR of 5.6 [Table 5] and recessive model (DD vs. ID + II) (P = 0.02) with adjusted OR of 4 [Table 6] in the present showed association with hypertension which was on par with a study on Chinese population (additive model, II vs. ID + DD with adjusted OR of 1.43 and recessive model, DD vs. ID + II with adjusted OR of 1.79).[21] We did a DNA Sanger sequencing to confirm the ACE I/D genetic polymorphism in our study population. Pharmacogenetics helps us to understand the treatment outcome of a particular drug due to the genetic polymorphism of a signal gene, i.e., individualising genetic variability which could alter a drug response.[22] In the Malay male hypertensive population, ACE I/D gene polymorphism showed an association in response to ACE inhibitors (enalapril or lisinopril). It was observed that the DD genotype had better control of high blood pressure with enalapril or lisinopril, 20 mg once daily, than II or ID genotype subjects.[11] Another pharmacogenetic study with Greek hypertensive patients shows that fosinopril, 20 mg once daily, lowers blood pressure in the DD genotype, while the II and ID genotypes didn’t show any significant reduction in blood pressure.[23] Some global studies also contradict that ACE I/D gene polymorphism and angiotensin receptor blocker, losartan in the Danish population,[24] valsartan in the Japanese population,[25] and telmisartan in the Spanish population.[26] did not affect blood pressure reduction. In our study, it was observed that calcium channel blocker, amlodipine (5 mg/day) showed better control of blood pressure in hypertensive patients with ACE II (76.1%) than patients with ACE DD (43.7%) genotypes [Table 7] whereas, angiotensin receptor blocker, telmisartan (20 mg/day) showed better control of blood pressure in hypertensive patients with ACE DD (83.3%) than patients with ACE II (43.7%) genotypes [Table 8]. Hypertensive patients with ACE ID genotypes did not show a significant lowering of blood pressure [Table 9]. Comprehensive lifestyle interventions, and DASH diet along with pharmacological therapy have shown a lowering of blood pressure in various studies. But some hypertensive individuals do not achieve the optimum blood pressure despite the therapy. Individualizing or customizing the therapy with the assistance of pharmacogenetics for patients with poor drug response or individuals with a higher genetically determined risk of adverse effects, along with lifestyle modification practices, would be a better approach for the management of hypertension. Limitations The present study has certain limitations. The sample size for the questionnaire survey in the present study was small compared to the prevalence of hypertension in India. Hence, the findings cannot be generalized and extrapolated to the entire population in the country. Cross-sectional studies have their own limitations in explaining the temporal ambiguity on whether patients daily practised the lifestyle interventions, as the subject’s answer may be biased. Study samples for the pharmacogenetic study were relatively small to infer a large population. Even though the study sample was small, the present study has relevant information regarding factors that might lead to both poor and better control of hypertension. Conclusion Our study shows that hypertensive patients who adhered to lifestyle modification practices along with individualized drug therapy had significant control of hypertension. ACE I/D gene polymorphism of the study subject was significantly associated with hypertension when compared to control subjects, and the distribution of genotypes II, ID, and DD in the controls and patients differed significantly from the expected under the Hardy–Weinberg Equilibrium. The percentage of the ACE ID genotype was higher in the control group as compared to the hypertensive group. Henceforth, the ACE ID genotype could be considered a protective factor against hypertension. Amlodipine showed better control of blood pressure in hypertensive patients with the ACE II genotype, and Telmisartan showed a better drug response in hypertensive patients with the ACE DD genotype. To conclude, the present study could be taken as a reference to analyse the impact of lifestyle modification practices along with pharmacogenetics on a larger and different geographic hypertensive population. Authors contributions FR, GK: Conception and design. FR, SE, SA, KP: Acquisition of data. FR, SE, SA, AB: Analysis and interpretation of data. FR, GK, NM: Drafting the article. GK, NM: Final approval of the version to be submitted. Ethical consideration For the present study, ethical clearance was obtained from the host institution (Ref. No. 002/SBMC/IHEC/2015-70). Consent to participate Informed consent for the study was obtained from the participants based on the willingness for participation. Confidentiality and privacy were maintained based on Helsinki declaration throughout the study. Data availability statement The data that supports the findings of this study are available from the corresponding author on reasonable request. Authors statement The manuscript has been read and approved by all the authors and the requirements for authorship as stated above has been met. Each author believes that the manuscript represents honest work. Conflict of interest The authors declare that they have no competing interests.